Organization | China Meitan General Hospital

China Meitan General Hospital Report issue

Academic/Hospital Phase 1 Phase 4

Founded: Beijing China (1993)

Organization Overview

First Clinical Trial

2012

NCT03084809

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

China Meitan General Hospital

Active Ingredients

Drugs in Phase 4 Trials (4)

cytokine induced killer cells (1 trial)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Drugs in Phase 1 Trials (2)

autologous csr t (1 trial)

mesothelin car t cells (1 trial)

Drugs in Other Trials (4)

autologous blood (1 trial)

midazolam (versed) (1 trial)

mitomycin (mutamycin) (1 trial)

remimazolam (Byfavo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Neoplasms (Phase 1)

Postoperative Complications (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 10